In addition, NSCLC harboring driver molecular aberrations such as EGFR mutations, which exhibit lesser mutational loads have been shown to be relatively resistant to immune checkpoint inhibition [170], a finding supported by a recently published meta-analysis on the prediction of response in NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.